ConforMIS (NASDAQ:CFMS) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, February 13th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.
Shares of ConforMIS (NASDAQ CFMS) opened at $1.34 on Tuesday. The firm has a market capitalization of $60.69 and a price-to-earnings ratio of -1.00. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.38 and a current ratio of 6.19. ConforMIS has a one year low of $1.28 and a one year high of $8.61.
CFMS has been the subject of several research reports. BTIG Research reissued a “buy” rating and set a $4.00 price objective on shares of ConforMIS in a research note on Wednesday, January 10th. Zacks Investment Research lowered ConforMIS from a “buy” rating to a “hold” rating in a research note on Tuesday, October 31st. Finally, JPMorgan Chase & Co. lowered ConforMIS from a “neutral” rating to an “underweight” rating in a research note on Tuesday, January 2nd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $5.54.
An institutional investor recently raised its position in ConforMIS stock. State Street Corp lifted its holdings in ConforMIS Inc (NASDAQ:CFMS) by 1.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 594,583 shares of the medical instruments supplier’s stock after buying an additional 8,693 shares during the period. State Street Corp owned about 1.33% of ConforMIS worth $2,550,000 as of its most recent SEC filing. Institutional investors own 35.37% of the company’s stock.
ConforMIS Company Profile
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.